Cerebain Biotech (CBBT) 10-Q12 Nov 132014 Q1 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
Document and Entity Information	Sep. 30, 2013	Nov. 12, 2013
Document And Entity Information	'	'
Entity Registrant Name	'DISCOUNT DENTAL MATERIALS, INC.	'
Entity Central Index Key	'0001453099	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-13	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--06-30	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	33,580,001
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Current assets:	'	'
Cash and cash equivalents	$453	$8
Prepaid expenses	957,968	1,533
Total current assets	958,421	1,541
Long-term assets:	'	'
Patent rights	83,900	83,900
Total long-term assets	83,900	83,900
Total assets	1,042,321	85,441
Current liabilities:	'	'
Accounts payable	101,124	81,154
Related party payables	151,778	105,006
Notes payable to stockholders	4,720	2,000
Accrued payroll and taxes	'	12,880
Related party notes payable	401,647	424,115
Total current liabilities	659,269	625,155
Long term liabilities:	'	'
Convertible note to stockholders, net of debt discount of $342,794 and $305,882, respectively	464,706	319,118
Total Long term liabilities	464,706	319,118
Total liabilities	1,123,975	944,273
Stockholders' deficit	'	'
Preferred stock ($0.001 par value: 1,000,000 shares authorized; none issued and outstanding)	'	'
Common stock ($0.001 par value: 249,000,000 shares authorized; 33,580,001 and 31,580,001 shares issued and outstanding at September 30 and June 30, 2013 respectively	33,580	31,580
Additional paid in capital	3,396,442	1,895,617
Deficit accumulated during the development stage	-3,511,676	-2,786,029
Total stockholders' deficit	-81,654	-858,832
Total liabilities and stockholders' deficit	$1,042,321	$85,441

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) (USD $)	Sep. 30, 2013	Jun. 30, 2013
Long term liabilities:	'	'
Net of debt discount	$342,794	$305,882
Stockholders' deficit	'	'
Preferred Stock, par value	$0.00	$0.00
Preferred Stock, shares authorized	1,000,000	1,000,000
Common Stock, par value	$0.00	$0.00
Common Stock, shares authorized	249,000,000	249,000,000
Common Stock, shares issued	33,580,001	31,580,001
Common Stock, shares outstanding	33,580,001	31,580,001

Unaudited_Condensed_Consolidat

Unaudited Condensed Consolidated Statements Of Operations (USD $)	3 Months Ended		43 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Operating Expenses	'	'	'
Selling, general and administrative expenses	$481,399	$153,090	$2,585,470
Research and development costs	88,200	108,500	200,778
Depreciation	'	214	1,711
Marketing expenses	53,341	'	56,976
Total operating expenses	622,940	261,804	2,844,935
Other Income (Expense)	'	'	'
Accretion of debt discount	83,088	16,875	225,019
Interest expense	19,619	7,080	44,722
Purchase of shell	'	'	397,000
Total other income (expense)	102,707	23,955	666,741
Net operating loss	-725,647	-285,759	-3,511,676
Loss before income taxes	-725,647	-285,759	-3,511,676
Income taxes	'	'	-3,511,676
Net loss	($725,647)	($285,759)	($3,511,676)
Loss per share:	'	'	'
Basic and diluted loss per share	($0.02)	($0.01)	'
Basic and diluted weighted average shares outstanding	32,927,827	31,180,001	'

Unaudited_Condensed_Consolidat1

Unaudited Condensed Consolidated Statements Of Cash Flows (USD $)	3 Months Ended		43 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net loss	($725,647)	($285,759)	($3,511,676)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	'	214	1,711
Accretion of debt discount	83,088	16,875	225,019
Warrants issued for research and development	49,200	108,500	157,700
Stock compensation related to stock options	61,625	'	308,125
Stock issued for services	318,000	'	630,000
Supplies contributed for founder's shares	'	'	10,650
Changes in operating assets and liabilities:	'	'	'
Accounts payable	19,970	-6,630	101,124
Related party payables	46,772	20,309	543,393
Prepaid expenses	-2,435	-15,849	-3,968
Accrued payroll and taxes	-12,880	'	'
Net cash used in operating activities	-162,307	-162,340	-1,537,922
Cash flows from investing activities:	'	'	'
Capitalized patent costs	'	'	-27,300
Purchases of computer equipment	'	'	-1,711
Net cash used in investing activities	'	'	-29,011
Cash flows from financing activities:	'	'	'
Founders capital contribution	'	'	3,250
Proceeds from issuance of common stock and warrants, net of offering costs	'	'	791,884
Notes payable to related parties	1,500	'	2,000
Repayment of notes payable to related parties	-23,968	'	-41,968
Repayment of notes payable to stockholders	-1,000	'	-20,490
Notes payable to stockholders	186,220	160,000	832,710
Net cash flows provided by financing activities:	162,752	160,000	1,567,386
Net change in cash and cash equivalents	445	-2,340	453
Cash and cash equivalents- beginning of period	8	4,185	'
Cash and cash equivalents- end of period	453	1,845	453
Supplemental disclosure of non cash activities:	'	'	'
Interest	'	'	'
Income tax	'	'	'
Supplemental disclosure on non-cash investing and financing activities:	'	'	'
Acquisition of patent rights for related party payable and common stock issuable	'	'	56,600
Issuance of common stock issuable	'	'	6,600
Beneficial conversion feature on convertible note	120,000	'	567,813
Conversion of related party payables into notes payable	'	'	441,615
Conversion of short term notes payable into long term note payable	'	'	$240,000

ORGANIZATION_AND_PRINCIPAL_ACT

ORGANIZATION AND PRINCIPAL ACTIVITIES	3 Months Ended
ORGANIZATION AND PRINCIPAL ACTIVITIES	Sep. 30, 2013
Organization And Principal Activities	'
ORGANIZATION AND PRINCIPAL ACTIVITIES	'
ORGANIZATION AND PRINCIPAL ACTIVITIES	The financial statements as of September 30, 2013 and for the three months ended September 30, 2013 and 2012 have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information on the same basis as the annual financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company's financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. They do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company's audited financial statements and notes thereto for the year ended June 30, 2013 included on Form 10-K/A filed with the Securities and Exchange Commission on October 4, 2013.

BASIS_OF_PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
BASIS OF PRESENTATION	Sep. 30, 2013
Basis Of Presentation	'
BASIS OF PRESENTATION	'
	The Company operates in one segment in accordance with accounting guidance Financial Accounting Standards Board (“FASB”) ASC Topic 280, Segment Reporting. Our Principal Executive Officer has been identified as the chief operating decision maker as defined by FASB ASC Topic 280.

	The Accounting Standards Codification ("Codification" or "ASC") is the source of authoritative accounting principles recognized by the FASB to be applied by nongovernmental entities in the preparation of financial statements in accordance with generally accepted accounting principles in the United States ("GAAP"). Rules and interpretive releases of the Securities and Exchange Commission ("SEC") issued under authority of federal securities laws are also sources of GAAP for SEC registrants.

	Description of Business

	Development Stage Company

	The Company is a development stage company as defined by ASC section 915-10-20. Although the Company’s planned principal operations have commenced it is still devoting substantially all of its efforts on establishing the business. All losses accumulated since inception has been considered as part of the Company's development stage activities.

	Fiscal year end

	The Company’s fiscal year end is June 30.

	Going Concern

	The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had a deficit accumulated during the development stage of $3,511,676 and $2,786,029 at September 30, 2013 and June 30, 2013, respectively, and had a net loss of $725,647 and $285,759 for the three months ended September 30, 2013 and 2012, respectively, and net cash used in operating activities of $162,307 and $162,340 for the three months ended September 30, 2013 and 2012, respectively, with no revenue earned since inception. These matters, among others, raise substantial doubt about our ability to continue as a going concern.

	While the Company is attempting to commence operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

	The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

SUMMARY_OF_SIGNIFICANT_ACCOUNT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Sep. 30, 2013
Summary Of Significant Accounting Policies	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	This summary of significant accounting policies of the Company is presented to assist in understanding the Company’s financial statements. The financial statements and notes are representations of the Company’s management, which is responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States and have been consistently applied in the preparation of the financial statements.

	Use of Estimates

	The preparation of these financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others: useful lives and residual values of long-lived assets, the valuation of equity instruments and the valuation of warrants and options. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

	Principles of Consolidation

	The accompanying condensed consolidated financial statements include the accounts of Discount Dental Materials, Inc. and its wholly-owned subsidiary, Cerebain Biotech Corp. (collectively hereinafter referred to as the “Company”). There are no material intercompany transactions.

	Revenue Recognition

	The Company expects to recognize revenues in accordance with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”.

	Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.

	Cash and Cash Equivalents

	For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of six months or less to be cash equivalents. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses.

	Income Taxes

	The Company is subject to income taxes in the U.S. Significant judgment is required in evaluating our uncertain tax positions and determining our provision for income taxes. In accordance with FASB ASC Topic 740, “Income Taxes,” the Company provides for the recognition of deferred tax assets if realization of such assets is more likely than not.

	The Company accounts for income tax under the provisions of FASB ASC Topic 740, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized.

	Advertising Costs

	Advertising costs are recorded as general and administrative expenses when they are incurred. Advertising costs charged to operations for the three months ended September 30, 2013 and 2012 were $53,341 and none, respectively, and are included in general and administrative expenses in the accompanying consolidated statements of operations.

	Research and Development

	The Company expenses the cost of research and development as incurred. Research and development costs charged to operations for the three months ended September 30, 2013 and 2012 were $88,200 and $108,500, respectively, and are included in research and development costs in the accompanying consolidated statements of operations.

	Long-lived Assets

	The Company’s long-lived assets and other assets (consisting of property and equipment and purchased intangible assets with finite useful lives) are reviewed for impairment in accordance with the guidance of the FASB Topic ASC 360, “Property, Plant, and Equipment”, and FASB ASC Topic 205 “Presentation of Financial Statements”. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Through September 30, 2013, the Company had not experienced impairment losses on its long-lived assets. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.

	Convertible Debt

	In accordance with ASC Topic 470-20, “Debt with Conversion and Other Options”, conventional convertible debt is a financial instrument in which the holder may only realize the value of the conversion option by exercising the option and receiving the entire proceeds in a fixed number of shares or the equivalent amount of cash. Conventional convertible debt with a non-detachable conversion feature that does not contain a cash settlement option, and is not accounted for as a derivative, is recorded as a debt instrument in its entirety.

	Non-Cash Equity Transactions

	Shares of equity instruments issued for non-cash consideration are recorded at the fair value of the consideration received based on the market value of services to be rendered, or at the value of the stock given, considered in reference to contemporaneous cash sale of stock.

	Accounting for Derivative Financial Instruments

	The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, “Derivative Instruments and Hedging: Contracts in Entity’s Own Equity” (“ASC Topic 815-40”). The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.

	Fair Value of Financial Instruments

	The Company applies the provisions of accounting guidance, FASB Topic ASC 825 that requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2013, and June 30, 2013, the fair value of cash, prepaid expenses, accounts payable, related party payables, and notes payable to stockholders approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.

	Fair Value Measurements

	FASB ASC Topic 825 “Financial Instruments,” requires disclosure about fair value of financial instruments.

	The FASB ASC Topic 820, Fair Value Measurements and Disclosures, clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.

	The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.

	·	Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.

·	Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).

·	Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.

Concentrations, Risks, and Uncertainties

The Company is a startup company subject to the substantial business risks and uncertainties inherent to such an entity, including the potential risk of business failure.

Basic and Diluted Earnings Per Share

Basic earnings (loss) per share is based on the weighted-average number of shares of common stock outstanding. Diluted earnings (loss) per share is based on the weighted-average number of shares of common stock outstanding adjusted for the effects of common stock that may be issued as a result of the following types of potentially dilutive instruments:

·	Warrants,

·	Convertible notes,

·	Employee stock options, and

·	Other equity awards, which include long-term incentive awards.

The FASB ASC Topic 260, Earnings Per Share, requires the Company to include additional shares in the computation of earnings per share, assuming dilution. The additional shares included in diluted earnings per share represent the number of shares that would be issued if all of the Company’s outstanding dilutive instruments were converted into common stock.

Diluted earnings per share are based on the assumption that all dilutive options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options, warrants, and convertible notes are assumed to be exercised at the time of issuance, and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

Basic and diluted earnings (loss) per share are the same since the Company had net losses for all periods presented and including the additional potential common shares would have an anti-dilutive effect.

Subsequent Events

The Company follows the guidance in ASC Topic 85, “Subsequent Events” (“ASC 855”), which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. ASC 855 sets forth (i) the period after the balance sheet date during which management of a reporting entity evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (ii) the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements, and (iii) the disclosures that an entity should make about events or transactions that occurred after the balance sheet date.

Recent Accounting Pronouncements

The Company has evaluated new accounting pronouncements that have been issued and are not yet effective for the Company and determined that there are no such pronouncements expected to have an impact on the Company’s future financial statements.

Reclassifications

Certain reclassifications have been made to the condensed consolidated financial statements for prior periods in order to conform to the current period presentation.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
COMMITMENTS AND CONTINGENCIES	Sep. 30, 2013
Commitments And Contingencies	'
COMMITMENTS AND CONTINGENCIES	'
	Employment Agreements

	On June 15, 2013, the Company entered into an employment agreement with Eric Clemons. Under the terms of the agreement, Mr. Clemons shall be paid an annual salary of One Hundred Fifty-Six Thousand Dollars ($156,000.00), shall be entitled to a bonus of $40,000 upon delivery to the company of a prototype medical device from Sonos Models Inc., and should he be responsible for DDOO consolidating with or merge into another corporation or convey all or substantially all of its assets to another corporation, will receive a cash bonus calculated using a Lehman formula of 5% for the first $1,000,000, 4% for the second $1,000,000, 3% for the third $1,000,000, 2% for the fourth $1,000,000, and 1% thereafter. In addition, the Company has issued Mr. Clemons an option to acquire up to 1,000,000 Shares of our Common Stock, fully paid and non-assessable at an exercise price of $0.50 per share subject to a vesting schedule. On August 30, 2013, the Company entered into an addendum to this agreement in which Mr. Clemons will be entitled to a stock award of 250,000 shares of our common restricted stock if, within 24 months, there is a reorganization of the company. Mr. Clemons has agreed to defer the aforementioned annual salary and accept a consulting fee for the same amount.

	On June 15, 2013, the Company entered into an employment agreement with Wesley Tate. Under the terms of the agreement, Mr. Tate shall be paid an annual salary of One Hundred Five Thousand Dollars ($105,000.00) and shall be entitled to a bonus of $20,000 upon delivery to the company of a prototype medical device form Sonos Models, Inc. In addition, the Company has issued Mr. Tate an option to acquire up to 500,000 Shares of our Common Stock, fully paid and non-assessable at an exercise price of $0.50 per share subject to a vesting schedule. On August 30, 2013, the Company entered into an addendum to this agreement in which Mr. Tate will be entitled to a stock award of 250,000 shares of our common restricted stock if, within 24 months, there is a reorganization of the company. Mr. Tate has agreed to defer the aforementioned annual salary and accept a consulting fee for the same amount.

	On June 1, 2013, the Company entered into a consulting agreement with Gerald DeCiccio. Under the terms of the agreement, Mr. DeCiccio will be paid a cash retainer of $5,000 per quarter, payable at the beginning of a quarter; $1,000 per major committee meeting as contemplated in the respective committee charter, payable at the beginning of the subsequent quarter; $2,500 per quarter, payable at the beginning of a quarter, for Chairman of the Audit Committee; and $1,000 per quarter, payable at the beginning of a quarter, for Chairman of any other board committee. In addition, he will also be issued 100,000 DDOO common restricted shares annually. The first issuance of 100,000 shares was on the Effective Date of this Agreement. Additional issuances will be made each year on January 1 thereafter. These shares will be fully vested on the date issued. On August 30, 2013, the Company entered into an addendum to this agreement in which Mr. DeCiccio will be entitled to a stock award of 250,000 shares of our common restricted stock if, within 24 months, there is a reorganization of the company.

	Contracts

	On September 24, 2012, the Company entered into an agreement with medical device product development company Sonos Models, Inc. (“Sonos”) to build up to three medical device prototypes to be used for testing. The agreement calls for a total cash payment of up to $400,000 and the issuance of warrants to purchase up to 650,000 shares of the Company’s common stock, with the cash payments and warrants to be issued in stages once certain developmental thresholds are achieved. Any warrants issued under this agreement will be immediately exercisable, will be eligible for cashless exercise at the option of the holder and will have a term of three years from the date of the issuance and an exercise price based on the fair market value of the stock on the date of completion of the phase. Pursuant to the agreement, the Company agreed to the following schedule:

	i) Upon signing the agreement the Company issued Sonos warrants to purchase 50,000 shares of the Company’s common stock. The warrants have an exercise price of $0.20 per share.

	ii) Phase 1 - Sonos will conduct a search of literature, patents, and sources for information to guide the definition of the device requirements, including, but not limited to, reviewing Dr. Saini’s patent, review other patents related to omentum, fluid extraction, and collection, stimulation, search medical literature for omentum texts, articles, research clinical studies related to the use of omentum in the treatment of omentum. In exchange for the services, the Company will pay Sonos a cash payment of approximately $20,000 and 50,000 warrants upon completion of the phase.

	iii) Phase 2 - Sonos will define the design objective in terms of materials, fabrication, technology, and performance. In exchange for the services, the Company will pay Sonos a cash payment of approximately $19,000 and 50,000 warrants upon completion of the phase.

	iv) Phase 3 - Sonos will develop a minimum of three design concepts that meet the design objectives outlined in Phase II, and document the designs in sketches, drawings, and draft specifications and estimate schedule, capital, and production costs for each approach. In exchange for these services, the Company will pay Sonos a cash payment of $12,500 and 100,000 warrants upon completion of the phase.

	v) Phase 4 - Sonos will review concepts from Phase 3 and choose two or more of the design concepts for the development of prototypes for testing in Phase 5 (which will be pursuant to a subsequent agreement between the parties). In exchange for these services, the Company will pay Sonos a cash payment of up to $350,000 and 100,000 warrants for each of the three prototypes for a total of 300,000 warrants.

	As of September 30, 2013, Sonos was in Phase 3 of the above development schedule and we have issued them warrants to purchase 50,000 shares of our common stock and paid them $25,000. In October of 2013, the company paid Sonos Product Development the remaining balance of $14,000 for work performed in Phases 1 and 2. The Company intends to issue the 100,000 warrants due for work completed on Phase 1 and 2 during the 2nd Quarter of fiscal 2014. The company has recognized an expense of $49,200 for these warrants during the three-month period ended September 30, 2013. In addition, the Company has entered into a consulting contract with IDC Consulting and Investors LLC who will assist the Company with necessary introductions to medical device testing facilities in Uzbekistan.

	Consulting Agreements

	The Company had a consulting agreement with its officer, director, and stockholder under which he was compensated $5,000 per month, plus medical benefits. This contract, as amended on January 1, 2012, was for twenty-four (24) months beginning January 2012 (“Initial Term”), automatically renewable for two (2) successive twelve (12) month terms after the Initial Term (“Renewal Term”), and terminable with six month notice during the Renewal Term. On January 18, 2013, the contract was terminated by both parties, notwithstanding the aforementioned termination provisions, with no additional costs owed subsequent to December 31, 2012. The amount of $116,700 owed under the contract as of December 31, 2012 was converted into a note payable (see Note 6).

	The Company has a consulting agreement with a stockholder to provide accounting and administrative support, under which she is compensated $1,500 per month. This contract was for twelve (12) months beginning September 2010 (“Initial Term”), automatically renewable for one (1) successive twelve (12) month term after the Initial Term (“Renewal Term”), and terminable with six month notice during the Renewal Term. This contract is currently on a month to month basis and can be terminated given 30 days written notice.

	In addition, the Company had consulting agreements with two (2) of its stockholders, under which the Company compensated each of these stockholders $10,000 per month plus medical benefits. These contracts, as amended on January 1, 2012, were for twenty-four (24) months beginning January 2012 (“Initial Term”), automatically renewable for two (2) successive twelve (12) month terms after the Initial Term (“Renewal Term”), and terminable with six month notice during the Renewal Term. On January 18, 2013, these contracts were terminated by both parties, notwithstanding the aforementioned terminable conditions, with no additional costs owed subsequent to December 31, 2012. The amounts totaling $240,000 owed under these contracts as of December 31, 2012 were converted into a note payable (see Note 6).

	The Company has a consulting agreement with an individual to provide assistance in the marketing of the company’s biomedical products, under which he is compensated $225 per hour and an engagement fee of 25,000 shares of the Company’s common stock. This contract is for twelve (12) months beginning March 2013, and may be renewed or extended for any period as may be agreed by the parties. Either party may terminate this agreement by providing the other with thirty (30) days written notice of such termination.

	The Company has a consulting agreement with an individual to provide assistance in the introduction of the company to medical device testing organization and to facilitate access to doctors in Uzbekistan, under which he is compensated 250,000 shares of the Company’s common stock. This contract is for twelve (12) months beginning April 2013, and may be renewed or extended for any period as may be agreed by the parties. Either party may terminate this agreement by providing the other with thirty (30) days written notice of such termination.

	The Company has an engagement agreement with a company to provide financial advisor services, under which they are paid an engagement fee of $45,000 and 25,000 shares of the Company’s common stock. This contract was for six (6) months beginning March 2013, unless extended by mutual written consent or earlier terminated. This contract was not renewed.

	The Company has consulting agreements with four individuals to provide assistance in the marketing of its biomedical products, under which they are compensated an aggregate 1.6 million shares of the Company’s common stock. These contracts are for twelve (12) months beginning July 2013 (“Initial Term”), and may be renewed or extended for any period as may be agreed by the parties. Any of the parties may terminate their respective agreement by providing thirty (30) days written notice of such termination.

	The Company has a consulting agreement with another individual to provide assistance in the marketing of its biomedical products, under which he is compensated 250,000 shares of the Company’s common stock. In addition, upon the successful introduction of the company to Investment Banking Firms, the Consultant shall receive 250,000 warrants, cashless, at $0.50 per share, 3 year term. This contract is for twelve (12) months beginning July 2013 (“Initial Term”), and may be renewed or extended for any period as may be agreed by the parties. Either party may terminate this agreement by providing the other with thirty (30) days written notice of such termination.

	On August 12, 2013, the Company entered into an Advertising Contract with Chineseinvestors.com, pursuant to which Chineseinvestors.com will provide advertising services to us for a twelve month marketing campaign, beginning August 12, 2013 and ending on August 12, 2014. Specifically, under the agreement, Chineseinvestors.com agrees to provide us with (i) a taped interview to be aired six (6) times on both Phoenix Satellite TV (USA), (ii) an interview to be aired on FM 96.1 KSQQ San Jose, CA, (iii) an interview to be aired on AM 1320 KXYZ Houston, TX, (iv) a link from its home page www.chineseinvestors.com to our company profile for a period of twelve (12) months and (v) a maximum of twelve (12) emails to its database members. Chineseinvestors.com will also provide all translation work for the interview, company profile, and email content. In exchange for these services we agreed to (i) pay Chineseinvestors.com a total of $125,000, with $20,000 due on August 14, 2013, and the remaining $105,000 payable in eleven equal monthly payments of $9,545, due the 12th of each month, beginning on September 12, 2013; and (ii) issue Chineseinvestors.com a total of 150,000 shares of our common stock, restricted in accordance with Rule 144, with piggy back registration rights.

	Patent License Agreement

	The Patent License agreement (see Note 5) provides for a one-time payment of $50,000 due within ninety (90) days of the date of signing of June 10, 2010 (as of the date of this filing, the one-time payment is fully paid), and a royalty payment of six (6) percent of the value of the net sales, as defined, generated from the sale of licensed products. The agreement also provides for yearly minimum royalty payments of $50,000 for each of the fourth, fifth, and sixth anniversary of the date of the agreement, and a yearly minimum royalty payment of $100,000 for each year thereafter during the term of the agreement. The term of the agreement shall continue until the patent in the intellectual property expires, unless terminated sooner under the provisions of the agreement, as defined.

	Legal

	The Company is not involved in any legal matters arising in the normal course of business. While incapable of estimation, in the opinion of the management, the individual regulatory and legal matters in which it might involve in the future are not expected to have a material adverse effect on the Company’s financial position, results of operations, or cash flows.

PATENT_RIGHTS

PATENT RIGHTS	3 Months Ended
PATENT RIGHTS	Sep. 30, 2013
Patent Rights	'
PATENT RIGHTS	'
	On June 10, 2010, the Company entered into a Patent License Agreement under which the Company acquired the exclusive rights to certain intellectual property related to using omentum for treating dementia conditions. Under the agreement the Company paid rights fees of $50,000 to Dr. Saini, and the Company issued Dr. Saini 8,250,000 shares of our common stock, valued at $6,600 (based on the fair market value on the date of grant) restricted in accordance with Rule 144. As a result Dr. Saini became our largest shareholder. In addition, Dr. Saini will have the option to participate in the sale of equity by the Company in the future, up to ten percent (10%) of the money raised, in exchange for the applicable number of his shares.

	The patent will have an estimated useful life of 20 years based on the term of the patent. Amortization of the patent will begin when the patent is issued by the United States Patent and Trademark Office and put in use.

	Through September 30, 2013, the Company has paid legal fees totaling $30,217 related to the patent.

NOTES_PAYABLE_TO_STOCKHOLDERS

NOTES PAYABLE TO STOCKHOLDERS	3 Months Ended
	Sep. 30, 2013
Notes Payable To Stockholders	'
NOTES PAYABLE TO STOCKHOLDERS	'
	Short Term Note Payable

	New Note

	On June 30, 2013, the Company converted $84,915 of related party payables owed under consulting agreements, into related party notes payable. The notes mature on December 31, 2013 and accrues interest at two (2.0) percent per annum at maturity. As of September 30, 2013, the outstanding balance of the related party payables is $66,947.

	On June 14, 2013, the Company entered into an unsecured $2,000 promissory note with a stockholder. The note matures on September 14, 2013 and accrues interest at two (2.0) percent per annum at maturity. As of September 30, 2013, the outstanding balance of the related party payables is $2,000. The Company is currently in default and is in discussions with the noteholder to restructure the terms of the note.

	On January 18, 2013, the Company converted $356,700 of related party payables owed under consulting agreements, into related party notes payable. The notes mature on December 31, 2013 and accrue interest at seven and one-half (7.5) percent per annum at maturity. As of September 30, 2013, the outstanding balance of the related party payables is $332,700.

	Old Notes

	On June 12, 2012, the Company entered into an unsecured $75,000 principal amount promissory note with a stockholder. This note, as amended, matured on September 30, 2012 and accrued interest beginning on the maturity date at 7.5% per annum. The Company determined that imputed interest on the note for the period from the issuance date to maturity is immaterial to the financial statements. On July 25, 2012, the Company entered into an unsecured $100,000 promissory note with the same stockholder. This note matured on September 30, 2012 and accrued interest at seven and one-half (7.5) percent per annum at maturity. On August 30, 2012, the Company entered into an unsecured $60,000 promissory note with the same stockholder. The terms of the note had not been negotiated as of the date of issuance. On November 1, 2012 the Company restructured the terms of these notes with the noteholder as described below.

	On November 1, 2012, the Company entered into an unsecured $235,000 principal amount consolidation promissory note with a non-affiliate stockholder. The Consolidation Promissory Note is a consolidation of the foregoing promissory notes totaling $235,000 with the same Noteholder. Such notes were voided as a result, however, the accrued interest on such notes is still owed and included with the accrued interest of the Consolidation Promissory Note until paid. The Company did not receive additional funds under the Consolidation Promissory Note, as it was a consolidation of prior notes owed to Noteholder. Under the terms of the Consolidation Promissory Note, it matured January 31, 2013, and accrued interest at 7.5% per annum beginning November 1, 2012. On March 14, 2013 the Company restructured the terms of the note with the noteholder as described below.

	On December 27, 2012, the Company entered into an unsecured $10,000 promissory note with a stockholder. On March 14, 2013 the Company restructured the terms of the note with the noteholder as described below.

	Long Term Note Payable

	Old Notes

	On July 31, 2011, the Company entered into an unsecured $60,000 promissory note with a stockholder. This note matured on April 13, 2012 and accrued interest at six (6) percent per annum at maturity. On October 13, 2011, the Company entered into a $100,000 convertible note (“Convertible Note”) with the same stockholder. The Convertible Note matured on April 13, 2012, accrued interest at six (6) percent per annum, the holder was entitled to convert at $0.32 per share into our common stock, and provided for potential adjustments, as defined. To properly account for this transaction, the Company performed a detailed analysis to obtain a thorough understanding of the transaction, including understanding the terms of each instrument issued. In accordance with ASC Topic 470-20, “Debt with Conversion and Other Options”, conventional convertible debt is a financial instrument in which the holder may only realize the value of the conversion option by exercising the option and receiving the entire proceeds in a fixed number of shares or the equivalent amount of cash. Conventional convertible debt with a nondetachable conversion feature that does not contain a cash settlement option, and is not accounted for as a derivative, is recorded as a debt instrument in its entirety. In addition, there was no beneficial conversion feature since the conversion price was not lower than the estimated fair value of our common stock on the date of the transaction. On February 1, 2012, the Company entered into an unsecured $80,000 promissory note with the same stockholder. This note matured on April 13, 2012 and accrued interest at six (6) percent per annum. On June 18, 2012 the Company restructured the terms of these notes with the noteholder as described below.

	On June 18, 2012, the Company entered into a $240,000 principal amount convertible promissory note with a non-affiliate stockholder. The Consolidation Note is a consolidation of the foregoing Promissory and Convertible Notes totaling $240,000 with the same Noteholder. Such notes were voided as a result, however, the accrued interest on such notes is still owed and included with the accrued interest of the Consolidation Note until paid. The Company did not receive additional funds under the consolidation note, as it was a consolidation of prior notes owed to Noteholder, but Noteholder has loaned the Company an additional $245,000 under the terms of separate promissory notes (non-convertible), as described above. Under the terms of the Consolidation Note, it was scheduled to mature June 30, 2014, accrued interest at 6% per annum beginning July 1, 2012, was convertible into shares of our common stock at $0.32 per share, but only if such conversion would not cause the Noteholder to own more than 9.9% of our outstanding common stock, and contained piggyback registration rights. The issuance was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, and the investor was sophisticated and familiar with our operations at the time of the issuance of the shares.

	To properly account for this transaction, the Company performed a detailed analysis to obtain a thorough understanding of the transaction, including understanding the terms of each instrument issued, and any related derivatives entered into. The Company first reviewed ASC Topic 815, “Broad Transactions – Derivatives and Hedging” (“Topic 815”) to identify whether any equity-linked features in the Consolidation Note are freestanding or embedded. The Company determined that there were no free standing features. The Consolidation Note was then analyzed in accordance with Topic 815 to determine if the Consolidation Note should be accounted for at fair value and remeasured at fair value in income. The Company determined that the Consolidation Note did not meet the requirements of Topic 815 and therefore accounted for the Consolidation Note as conventional convertible debt.

	The Company then reviewed ASC Topic 470-20, “Debt with Conversion and Other Options”, and determined that the Consolidation Note met the criteria of a conventional convertible note and that the Consolidation Note had a beneficial conversion feature valued at $135,000, which was recorded as a debt discount against the face amount of the Consolidation Note, which is being accreted to interest expense over the 24 month term of the Consolidation Note. The Company used a recent sale of restricted stock to determine the fair value of the stock for purposes of calculating the beneficial conversion feature. On March 14, 2013 the Company restructured the terms of the note with the noteholder as described below. The unamortized debt discount of $83,000 was offset against additional paid-in capital.

	New Note

	On March 14, 2013, the Company entered into an unsecured $600,000 principal amount convertible promissory note with a non-affiliate stockholder. The Consolidation Note is a consolidation of the foregoing Promissory and Convertible Notes totaling $485,000 with the same Noteholder. Such notes were voided as a result, however, the accrued interest on such notes is still owed and included with the accrued interest of the Consolidation Note until paid. The Company received additional funds totaling $115,000 under the Consolidation Note. Under the terms of the Consolidation Note, it matures July 15, 2014, accrues interest at 7.5% per annum beginning March 1, 2013, is convertible into shares of our common stock at $0.30 per share, but only if such conversion would not cause the Noteholder to own more than 9.9% of our outstanding common stock, and contains piggyback registration rights. The issuance was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, and the investor was sophisticated and familiar with our operations at the time of the issuance of the shares.

	To properly account for this transaction, the Company performed a detailed analysis to obtain a thorough understanding of the transaction, including understanding the terms of each instrument issued, and any related derivatives entered into. The Company first reviewed ASC Topic 815, to identify whether any equity-linked features in the Consolidation Note are freestanding or embedded. The Company determined that there were no free standing features. The Consolidation Note was then analyzed in accordance with Topic 815 to determine if the Consolidation Note should be accounted for at fair value and remeasured at fair value in income. The Company determined that the Consolidation Note did not meet the requirements of Topic 815 and therefore accounted the Consolidation Note as conventional convertible debt. The Company then reviewed ASC Topic 470-20, and determined that the Consolidation Note met the criteria of a conventional convertible note and that the Consolidation Note had a beneficial conversion feature valued at $400,000, which was recorded as a debt discount against the face amount of the Consolidation Note, which is being accreted to interest expense over the 17 month term of the Consolidation Note. The Company used a recent sale of restricted stock to determine the fair value of the stock for purposes of calculating the beneficial conversion feature. On October 15, 2013 the Company restructured the terms of the note with the noteholder as described in Note 11.

	On June 4, 2013, the Company entered into an unsecured $25,000 principal amount convertible promissory note with a non-affiliate stockholder. Under the terms of the, it matures June 4, 2015, accrues interest at 8.0% per annum beginning July 1, 2013, is convertible into shares of our common stock at $0.50 per share and contains piggyback registration rights. The issuance was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, and the investor was sophisticated and familiar with our operations at the time of the issuance of the shares.

	On July 10, 2013, the Company entered into an unsecured $120,000 principal amount convertible promissory note with a non-affiliate stockholder. Under the terms of the Note, it matures July 10, 2015, accrues interest at 7.5% per annum beginning July 1, 2013, is convertible into shares of our common stock at $0.20 per share but only if such conversion would not cause the Noteholder to own more than 9.9% of our outstanding common stock and contains piggyback registration rights. The issuance was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, and the investor was sophisticated and familiar with our operations at the time of the issuance of the shares.

	To properly account for this transaction, the Company performed a detailed analysis to obtain a thorough understanding of the transaction, including understanding the terms of each instrument issued, and any related derivatives entered into. The Company first reviewed ASC Topic 815, to identify whether any equity-linked features in the Note are freestanding or embedded. The Company determined that there were no free standing features. The Note was then analyzed in accordance with Topic 815 to determine if the Note should be accounted for at fair value and remeasured at fair value in income. The Company determined that the Note did not meet the requirements of Topic 815 and therefore accounted for the Note as conventional convertible debt. The Company then reviewed ASC Topic 470-20, and determined that the Note met the criteria of a conventional convertible note and that the Note had a beneficial conversion feature valued at $120,000, which was recorded as a debt discount against the face amount of the Note, which is being accreted to interest expense over the 24 month term of the Note. The Company used a recent sale of restricted stock to determine the fair value of the stock for purposes of calculating the beneficial conversion feature. On October 15, 2013 the Company restructured the terms of the note with the noteholder as described in Note 11.

	On August 13, 2013, the Company entered into an unsecured $50,000 promissory note with a stockholder. The terms of the note have not been negotiated. On October 15, 2013 the Company restructured the terms of the note with the noteholder as described in Note 11.

	On September 16, 2013, the Company entered into an unsecured $12,500 principal amount convertible promissory note with a non-affiliate stockholder. Under the terms of the, it matures September 16, 2015, accrues interest at 7.5% per annum beginning October 1, 2013, is convertible into shares of our common stock at $0.20 per share and contains piggyback registration rights. The issuance was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, and the investor was sophisticated and familiar with our operations at the time of the issuance of the shares.

	Accrued interest on all notes payable to stockholders at September 30, 2013 totaled $57,685 and is included in related party payables.

	As of September 30, 2013, future maturities of notes payable are as follows:

	Fiscal year ending June 30,

	2014	$	401,647
	2015	$	807,500
	Total	$	1,209,147

STOCK_TRANSACTIONS

STOCK TRANSACTIONS	3 Months Ended
STOCK TRANSACTIONS	Sep. 30, 2013
Stock Transactions	'
STOCK TRANSACTIONS	'
	On August 27, 2013 the Company issued 400,000 shares of common stock to individuals as payment for consulting services per contracts dated July and August 2013. The aggregate Fair Market Value of these shares was $248,000 as the fair market value of the stock was $0.62. For the three-month periods ended September 30, 2013 and 2012, the Company recognized an expense of $62,000 and $0, respectively. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

	On July 23, 2013 the Company issued 1.6 million shares of common stock to individuals as payment for consulting services per contracts dated July 2013. The aggregate Fair Market Value of these shares was $1,024,000 as the fair market value of the stock was $0.64. For the three-month periods ended September 30, 2013 and 2012, the Company recognized an expense of $256,000 and $0, respectively. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

	On June 15, 2013, the Company entered into an employee agreement with Eric Clemons. The agreement calls for an issuance of options to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $0.50, subject to a vesting schedule. Fair Market Value of these options was approximately $821,675. As of September 30, 2013, 200,000 options to purchase the Company’s common stock have vested. For the three-month periods ended September 30, 2013 and 2012, the Company recognized an expense of $41,084 and $0, respectively, and for the period from inception through September 30, 2013 has recognized a total expense of $205,419.

	On June 15, 2013, the Company entered into an employee agreement with Wesley Tate. The agreement calls for an issuance of options to purchase up to 500,000 shares of the Company’s common stock at an exercise price of $0.50, subject to a vesting schedule. Fair Market Value of these options was approximately $410,825. As of September 30, 2013, 100,000 options to purchase the Company’s common stock have vested. For the three-month periods ended September 30, 2013 and 2012, the Company recognized an expense of $20,541 and $0, respectively, and for the period from inception through September 30, 2013 has recognized a total expense of $102,706.

	In 2013 the Company issued 25,000 shares of common stock to an individual as payment for consulting services per contract dated March 2013. The company recognized an expense of $10,000 as the fair market value of the shares was $0.40. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

	In 2013 the Company issued 100,000 shares of common stock to an individual as payment for consulting services per contract dated June 2013. The company recognized an expense of $100,000 as the fair market value of the shares was $1.00. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

	In 2013 the Company issued 250,000 shares of common stock to an individual as payment for consulting services per contract dated April 2013. The company recognized an expense of $182,500 as the fair market value of the shares was $0.73. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

	In 2013 the Company issued 25,000 shares of common stock to an individual as payment for consulting services per contract dated March 2013. The company recognized an expense of $19,500 as the fair market value of the shares was $0.78. This issuance was completed in accordance with Section 4(2) of the Securities Act in an offering without any public offering or distribution. These shares are restricted securities and include an appropriate restrictive legend.

	On June 10, 2010, the Company entered into a Patent License Agreement under which the Company acquired the exclusive rights to certain intellectual property related to using omentum for treating dementia conditions. Under the agreement the Company issued Dr. Saini 8,250,000 shares of our common stock, valued at $6,600 (based on the fair market value on the date of grant) restricted in accordance with Rule 144. As a result Dr. Saini became our largest shareholder. The issuance was an isolated transaction not involving a public offering pursuant to Section 4(2) of the Securities Act of 1933. In addition, Dr. Saini will have the option to participate in the sale of equity by the Company in the future, up to ten percent (10%) of the money raised, in exchange for the applicable number of his shares.

OPTIONS_AND_WARRANTS

OPTIONS AND WARRANTS	3 Months Ended
OPTIONS AND WARRANTS	Sep. 30, 2013
Options And Warrants	'
OPTIONS AND WARRANTS	'
	On June 15, 2013, the Company entered into an employee agreement with Eric Clemons. The agreement calls for an issuance of options to purchase up to 1,000,000 shares of the Company’s common stock at an exercise price of $0.50, subject to a vesting schedule. Fair Market Value of these options was approximately $821,675. As of September 30, 2013, 200,000 options to purchase the Company’s common stock have vested. For the three-month periods ended September 30, 2013 and 2012, the Company recognized an expense of $41,084 and $0, respectively, and for the period from inception through September 30, 2013 has recognized a total expense of $205,419.

	On June 15, 2013, the Company entered into an employee agreement with Wesley Tate. The agreement calls for an issuance of options to purchase up to 500,000 shares of the Company’s common stock at an exercise price of $0.50, subject to a vesting schedule. Fair Market Value of these options was approximately $410,825. As of September 30, 2013, 100,000 options to purchase the Company’s common stock have vested. For the three-month periods ended September 30, 2013 and 2012, the Company recognized an expense of $20,541 and $0, respectively, and for the period from inception through September 30, 2013 has recognized a total expense of $102,706.

	On July 1, 2011, the Company entered into a stock purchase agreement with a third party, under which the Company issued him 25,000 restricted common shares along with warrants to purchase an additional 12,500 shares with an exercise price of $0.80 and are exercisable for term of two years. The warrants expired July 2013.

	On May 17, 2011, the Company entered into a stock purchase agreement with a third party, under which the Company issued him 50,000 restricted common shares along with warrants to purchase an additional 25,000 shares with an exercise price of $0.80 and are exercisable for term of two years. The warrants expired May 2013.

	On September 24, 2012, the Company entered into an agreement with medical device product development company Sonos Models, Inc. (“Sonos”) to build up to three medical device prototypes to be used for testing. The agreement calls for a total cash payment of up to $400,000 and the issuance of warrants to purchase up to 650,000 shares of the Company’s common stock, with the cash payments and warrants to be issued in stages once certain developmental thresholds are achieved.

	Upon signing the agreement the Company issued Sonos warrants to purchase 50,000 shares of the Company’s common stock, valued at $108,500 (based on the fair market value on the date of grant). The warrants are immediately exercisable, cashless at the option of the holder, and have a term of three years and an exercise price of $0.20 per share.

	The Company analyzed the warrants issued (“Warrants”) in accordance with ASC Topic 815 to determine whether the Warrants meet the definition of a derivative under ASC Topic 815 and, if so, whether the Warrants meet the scope exception of ASC Topic 815, which is that contracts issued or held by the reporting entity that are both (1) indexed to its own stock and (2) classified in stockholders’ equity shall not be considered to be derivative instruments for purposes of ASC Topic 815. The provisions of ASC Topic 815 subtopic 40 “Determining Whether an Instrument (or Embedded Feature) Is Indexed to an Entity’s Own Stock” (“ASC Topic 815 subtopic 40”) apply to any freestanding financial instruments or embedded features that have the characteristics of a derivative, as defined by ASC Topic 815 and to any freestanding financial instruments that are potentially settled in an entity’s own common stock. The Company concluded these warrants should be treated as equity since they contain no provisions which would require the Company to account for the warrants as a derivative liability.

	During the year ended June 30, 2013, the Company issued 50,000 warrants. Using Black-Scholes, with a volatility of 235.52%, a risk-free interest rate of 0.27% and 0% dividend yield, these warrants were valued at $108,000 and expensed as Research and Development.

	During the period ended September 30, 2013, the Company recognized an expense for 100,000 warrants to be issued to Sonos. Using Black-Scholes, with a volatility of 100%, a risk free interest rate of 1.04% and 0% dividend yield, these warrants were valued at $49,200 and expensed as Research and Development.

	The options were valued on the date of issuance using the Black-Scholes value option pricing model with the following inputs: volatility of 100%; risk-free interest rate of 1.04%; expected term of 5 years; and 0% dividend yield.

	The following represents a summary of the Warrants outstanding at September 30, 2013 and changes during the years then ended:

		2014
		Warrants			Weighted Average
		Warrants			Exercise Price
	Outstanding, beginning of year		62,500		$	0.32
	Granted		100,000			0.2
	Exercised		-			-
	Expired/Forfeited		(12,500	)		0.8
	Outstanding, September 30, 2013		150,000		$	0.2
	Exercisable at September 30, 2013		150,000		$	0.2
	Incurred expense	$	157,200

	The following represents a summary of the Options outstanding at September 30, 2013 and changes during the years then ended:

		2014
		Options			Options Average
		Options			Exercise Price
	Outstanding, beginning of year		1,500,000		$	0.5
	Granted		-			-
	Exercised		-			-
	Expired/Forfeited		-			-
	Outstanding, September 30, 2013		1,500,000		$	0.5
	Exercisable at September 30, 2013		300,000		$	0.5
	Expected to be vested		1,200,000		$	0.5
	Incurred expense	$	308,125

RELATED_PARTY_TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
RELATED PARTY TRANSACTIONS	Sep. 30, 2013
Related Party Transactions	'
RELATED PARTY TRANSACTIONS	'
	Other than as set forth below, and as disclosed in Notes 4, 6, 7, and 8, the Company has not entered into or been a participant in any transaction in which a related person had or will have a direct or indirect material interest.

	On January 18, 2013, the Company converted $356,700 of related party payables owed under consulting agreements (see Note 4), into related party notes payable. The notes mature on December 31, 2013 and accrue interest at seven and one-half (7.5) percent per annum at maturity. As of September 30, 2013, the outstanding balance of the related party payables is $332,700.

	Included in related party payables at September 30, 2013 is $57,685 of accrued interest on notes payable to stockholders.

EARNINGS_PER_SHARE

EARNINGS PER SHARE	3 Months Ended
EARNINGS PER SHARE	Sep. 30, 2013
Loss per share:	'
EARNINGS PER SHARE	'
	FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings (loss) per share (EPS) computations.

	Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive.

	The total number of potential additional dilutive warrants outstanding for the three months ended September 30, 2013 and 2012 was 1,650,000 and 87,500, respectively. In addition, the convertible note converts at an exercise price of $0.30 of common stock. The warrants and shares underlying the convertible note were considered for the dilutive calculation but in periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

	The following table sets forth the computation of basic and diluted net income per share:

		For The Three Months ended
		September 30,
		2013			2012


	Net loss attributable to the common stockholders	$	(725,647	)	$	(285,759	)

	Basic weighted average outstanding shares of common stock		32,927,827			31,180,001
	Dilutive effect of options and warrants		-			-
	Diluted weighted average common stock and common stock equivalents		32,927,827			31,180,001

	Earnings (loss) per share:
	Basic and diluted	$	(0.02	)	$	(0.01	)

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	3 Months Ended
SUBSEQUENT EVENTS	Sep. 30, 2013
Subsequent Events	'
SUBSEQUENT EVENTS	'
SUBSEQUENT EVENTS	On October 15, 2013, the Company entered into an unsecured $970,000 principal amount convertible promissory note with a non-affiliate stockholder. The Consolidation Note is a consolidation of the Company’s previous Promissory and Convertible Notes totaling $770,000 with the same Noteholder. Such notes were voided as a result, however, the accrued interest on such notes is still owed and included with the accrued interest of the Consolidation Note until paid. The Company received additional funds totaling $200,000 under the Consolidation Note. Under the terms of the Consolidation Note, it matures October 15, 2015, accrues interest at 7.5% per annum beginning November 1, 2013, is convertible into shares of the Company’s common stock at $0.20 per share, but only if such conversion would not cause the Noteholder to own more than 9.9% of the Company’s outstanding common stock, and contains piggyback registration rights. The issuance was exempt from registration pursuant to Section 4(2) of the Securities Act of 1933, and the investor was sophisticated and familiar with the Company’s operations at the time of the issuance of the shares.

BASIS_OF_PRESENTATION_Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
BASIS OF PRESENTATION (Policies)	Sep. 30, 2013
Basis Of Presentation Policies	'
Development stage company	'
Development stage company	The Company is a development stage company as defined by ASC section 915-10-20. Although the Company’s planned principal operations have commenced it is still devoting substantially all of its efforts on establishing the business. All losses accumulated since inception has been considered as part of the Company's development stage activities.
Fiscal year end	'
Fiscal year end	The Company’s fiscal year end is June 30.
Going Concern	'
	The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company had a deficit accumulated during the development stage of $3,511,676 and $2,786,029 at September 30, 2013 and June 30, 2013, respectively, and had a net loss of $725,647 and $285,759 for the three months ended September 30, 2013 and 2012, respectively, and net cash used in operating activities of $162,307 and $162,340 for the three months ended September 30, 2013 and 2012, respectively, with no revenue earned since inception. These matters, among others, raise substantial doubt about our ability to continue as a going concern.

	While the Company is attempting to commence operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public or private offering. Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to generate revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

	The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

SUMMARY_OF_SIGNIFICANT_ACCOUNT1

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Sep. 30, 2013
Summary Of Significant Accounting Policies Policies	'
Use of Estimates	'
	The preparation of these financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of net sales and expenses during the reported periods. Actual results may differ from those estimates and such differences may be material to the financial statements. The more significant estimates and assumptions by management include among others: useful lives and residual values of long-lived assets, the valuation of equity instruments and the valuation of warrants and options. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.
Principles of Consolidation	'
	The accompanying condensed consolidated financial statements include the accounts of Discount Dental Materials, Inc. and its wholly-owned subsidiary, Cerebain Biotech Corp. (collectively hereinafter referred to as the “Company”). There are no material intercompany transactions.
Revenue Recognition	'
	The Company expects to recognize revenues in accordance with the guidelines of the Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 “Revenue Recognition”.

	Under SAB 104, four conditions must be met before revenue can be recognized: (i) there is persuasive evidence that an arrangement exists, (ii) delivery has occurred or service has been rendered, (iii) the price is fixed or determinable, and (iv) collection is reasonably assured.
Cash and Cash Equivalents	'
	For purposes of the statements of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of six months or less to be cash equivalents. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses.
Income Taxes	'
	The Company is subject to income taxes in the U.S. Significant judgment is required in evaluating our uncertain tax positions and determining our provision for income taxes. In accordance with FASB ASC Topic 740, “Income Taxes,” the Company provides for the recognition of deferred tax assets if realization of such assets is more likely than not.

	The Company accounts for income tax under the provisions of FASB ASC Topic 740, “Income Taxes”, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of the events that have been included in the financial statements or tax returns. Deferred income taxes are recognized for all significant temporary differences between tax and financial statements bases of assets and liabilities. Valuation allowances are established against net deferred tax assets when it is more likely than not that some portion or all of the deferred tax asset will not be realized.
Advertising Costs	'
	Advertising costs are recorded as general and administrative expenses when they are incurred. Advertising costs charged to operations for the three months ended September 30, 2013 and 2012 were $53,341 and none, respectively, and are included in general and administrative expenses in the accompanying consolidated statements of operations.
Research and Development	'
	The Company expenses the cost of research and development as incurred. Research and development costs charged to operations for the three months ended September 30, 2013 and 2012 were $88,200 and $108,500, respectively, and are included in research and development costs in the accompanying consolidated statements of operations.
Long-lived Assets	'
	The Company’s long-lived assets and other assets (consisting of property and equipment and purchased intangible assets with finite useful lives) are reviewed for impairment in accordance with the guidance of the FASB Topic ASC 360, “Property, Plant, and Equipment”, and FASB ASC Topic 205 “Presentation of Financial Statements”. The Company tests for impairment losses on long-lived assets used in operations whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of an asset to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the asset. If such asset is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds its fair value. Impairment evaluations involve management’s estimates on asset useful lives and future cash flows. Actual useful lives and cash flows could be different from those estimated by management which could have a material effect on our reporting results and financial positions. Fair value is determined through various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. Through September 30, 2013, the Company had not experienced impairment losses on its long-lived assets. However, there can be no assurances that demand for the Company’s products or services will continue, which could result in an impairment of long-lived assets in the future.
Convertible Debt	'
	In accordance with ASC Topic 470-20, “Debt with Conversion and Other Options”, conventional convertible debt is a financial instrument in which the holder may only realize the value of the conversion option by exercising the option and receiving the entire proceeds in a fixed number of shares or the equivalent amount of cash. Conventional convertible debt with a non-detachable conversion feature that does not contain a cash settlement option, and is not accounted for as a derivative, is recorded as a debt instrument in its entirety.
Non-Cash Equity Transactions	'
	Shares of equity instruments issued for non-cash consideration are recorded at the fair value of the consideration received based on the market value of services to be rendered, or at the value of the stock given, considered in reference to contemporaneous cash sale of stock.
Accounting for Derivative Financial Instruments	'
	The Company evaluates stock options, stock warrants or other contracts to determine if those contracts or embedded components of those contracts qualify as derivatives to be separately accounted for under the relevant sections of ASC Topic 815-40, “Derivative Instruments and Hedging: Contracts in Entity’s Own Equity” (“ASC Topic 815-40”). The result of this accounting treatment could be that the fair value of a financial instrument is classified as a derivative instrument and is marked-to-market at each balance sheet date and recorded as a liability. In the event that the fair value is recorded as a liability, the change in fair value is recorded in the statement of operations as other income or other expense. Upon conversion or exercise of a derivative instrument, the instrument is marked to fair value at the conversion date and then that fair value is reclassified to equity. Financial instruments that are initially classified as equity that become subject to reclassification under ASC Topic 815-40 are reclassified to a liability account at the fair value of the instrument on the reclassification date.
Fair Value of Financial Instruments	'
	The Company applies the provisions of accounting guidance, FASB Topic ASC 825 that requires all entities to disclose the fair value of financial instruments, both assets and liabilities recognized and not recognized on the balance sheet, for which it is practicable to estimate fair value, and defines fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of September 30, 2013, and June 30, 2013, the fair value of cash, prepaid expenses, accounts payable, related party payables, and notes payable to stockholders approximated carrying value due to the short maturity of the instruments, quoted market prices or interest rates which fluctuate with market rates.
Fair Value Measurements	'
	FASB ASC Topic 825 “Financial Instruments,” requires disclosure about fair value of financial instruments.

	The FASB ASC Topic 820, Fair Value Measurements and Disclosures, clarifies the definition of fair value for financial reporting, establishes a framework for measuring fair value and requires additional disclosures about the use of fair value measurements.

	The inputs or methodologies used for valuing securities are not necessarily an indication of the risk associated with investing in these securities. These inputs are summarized in the three broad levels listed below.

	·	Level 1 – observable market inputs that are unadjusted quoted prices for identical assets or liabilities in active markets.

	·	Level 2 – other significant observable inputs (including quoted prices for similar securities, interest rates, credit risk, etc.).

	·	Level 3 – significant unobservable inputs (including the Company’s own assumptions in determining the fair value of investments).

	The carrying value of financial assets and liabilities recorded at fair value is measured on a recurring or nonrecurring basis. Financial assets and liabilities measured on a non-recurring basis are those that are adjusted to fair value when a significant event occurs. The Company had no financial assets or liabilities carried and measured on a nonrecurring basis during the reporting periods. Financial assets and liabilities measured on a recurring basis are those that are adjusted to fair value each time a financial statement is prepared.
Concentrations, Risks, and Uncertainties	'
	The Company is a startup company subject to the substantial business risks and uncertainties inherent to such an entity, including the potential risk of business failure.
Basic and Diluted Earnings Per Share	'
	Basic earnings (loss) per share is based on the weighted-average number of shares of common stock outstanding. Diluted earnings (loss) per share is based on the weighted-average number of shares of common stock outstanding adjusted for the effects of common stock that may be issued as a result of the following types of potentially dilutive instruments:

	·	Warrants,

	·	Convertible notes,

	·	Employee stock options, and

	·	Other equity awards, which include long-term incentive awards.

	The FASB ASC Topic 260, Earnings Per Share, requires the Company to include additional shares in the computation of earnings per share, assuming dilution. The additional shares included in diluted earnings per share represent the number of shares that would be issued if all of the Company’s outstanding dilutive instruments were converted into common stock.

	Diluted earnings per share are based on the assumption that all dilutive options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options, warrants, and convertible notes are assumed to be exercised at the time of issuance, and as if funds obtained thereby were used to purchase common stock at the average market price during the period.

	Basic and diluted earnings (loss) per share are the same since the Company had net losses for all periods presented and including the additional potential common shares would have an anti-dilutive effect.
Subsequent Events	'
	The Company follows the guidance in ASC Topic 85, “Subsequent Events” (“ASC 855”), which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued or are available to be issued. ASC 855 sets forth (i) the period after the balance sheet date during which management of a reporting entity evaluate events or transactions that may occur for potential recognition or disclosure in the financial statements, (ii) the circumstances under which an entity should recognize events or transactions occurring after the balance sheet date in its financial statements, and (iii) the disclosures that an entity should make about events or transactions that occurred after the balance sheet date.
RecentAccounting Pronouncements	'
	The Company has evaluated new accounting pronouncements that have been issued and are not yet effective for the Company and determined that there are no such pronouncements expected to have an impact on the Company’s future financial statements.
Reclassifications	'
	Certain reclassifications have been made to the condensed consolidated financial statements for prior periods in order to conform to the current period presentation.

NOTES_PAYABLE_TO_STOCKHOLDERS_

NOTES PAYABLE TO STOCKHOLDERS (Tables)	3 Months Ended
NOTES PAYABLE TO STOCKHOLDERS (Tables)	Sep. 30, 2013
Notes Payable To Stockholders Tables	'
Future maturities of notes payable	'
	Fiscal year ending June 30,

	2014	$	401,647
	2015	$	807,500
	Total	$	1,209,147

OPTIONS_AND_WARRANTS_Tables

OPTIONS AND WARRANTS (Tables)	3 Months Ended
OPTIONS AND WARRANTS (Tables)	Sep. 30, 2013
Options And Warrants Tables	'
Summary of the warrants outstanding	'
		2014
		Warrants			Weighted Average
		Warrants			Exercise Price
	Outstanding, beginning of year		62,500		$	0.32
	Granted		100,000			0.2
	Exercised		-			-
	Expired/Forfeited		(12,500	)		0.8
	Outstanding, September 30, 2013		150,000		$	0.2
	Exercisable at September 30, 2013		150,000		$	0.2
	Incurred expense	$	157,200
summary of the options outstanding	'
		2014
		Options			Options Average
		Options			Exercise Price
	Outstanding, beginning of year		1,500,000		$	0.5
	Granted		-			-
	Exercised		-			-
	Expired/Forfeited		-			-
	Outstanding, September 30, 2013		1,500,000		$	0.5
	Exercisable at September 30, 2013		300,000		$	0.5
	Expected to be vested		1,200,000		$	0.5
	Incurred expense	$	308,125

EARNINGS_PER_SHARE_Tables

EARNINGS PER SHARE (Tables)	3 Months Ended
EARNINGS PER SHARE (Tables)	Sep. 30, 2013
Earnings Per Share Tables	'
Computation of basic and diluted net income per share	'
		For The Three Months ended
		September 30,
		2013			2012


	Net loss attributable to the common stockholders	$	(725,647	)	$	(285,759	)

	Basic weighted average outstanding shares of common stock		32,927,827			31,180,001
	Dilutive effect of options and warrants		-			-
	Diluted weighted average common stock and common stock equivalents		32,927,827			31,180,001

	Earnings (loss) per share:
	Basic and diluted	$	(0.02	)	$	(0.01	)

BASIS_OF_PRESENTATION_Details_

BASIS OF PRESENTATION (Details Narrative) (USD $)	3 Months Ended		43 Months Ended
BASIS OF PRESENTATION (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Jun. 30, 2013
Basis Of Presentation Details Narrative	'	'	'	'
Deficit accumulated during the development stage	$3,511,676	'	$3,511,676	$2,786,029
Net loss	725,647	285,759	3,511,676	'
Net cash used in operating activities	$162,307	$162,340	$1,537,922	'

SUMMARY_OF_SIGNIFICANT_ACCOUNT2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) (USD $)	3 Months Ended		43 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Summary Of Significant Accounting Policies Details Narrative	'	'	'
Advertising costs	$53,341	'	$56,976
Research and development costs	$88,200	$108,500	$200,778

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Commitments And Contingencies Details Narrative	'	'
Purchased warrants	$50,000	'
Paid amount for warrants	25,000	'
Recognized expense for warrants	49,200	'
Amount owed contract	'	116,700
Total owned amount	'	$240,000

PATENT_RIGHTS_Details_Narrativ

PATENT RIGHTS (Details Narrative) (USD $)	3 Months Ended
PATENT RIGHTS (Details Narrative) (USD $)	Sep. 30, 2013
Patent Rights Details Narrative	'
Paid legal fees	$30,217

NOTES_PAYABLE_TO_STOCKHOLDERS_1

NOTES PAYABLE TO STOCKHOLDERS (Details) (USD $)	Sep. 30, 2013
Fiscal year ending June 30,	'
2014	$401,647
2015	807,500
Total	$1,209,147

NOTES_PAYABLE_TO_STOCKHOLDERS_2

NOTES PAYABLE TO STOCKHOLDERS (Details Narrative) (USD $)	Sep. 30, 2013	Jun. 30, 2013	Jun. 14, 2013
Notes Payable To Stockholders Details Narrative	'	'	'
Converted related party payble	'	$84,915	'
Outstanding balance of related party paybles	66,947	'	'
Unsecured promissory note	'	'	2,000
Outstanding balance related party paybles	2,000	'	'
Per annum	2.00%	'	'
Accured intrest related party paybles	57,685	'	'
Outstanding balance of related party paybles	$332,700	'	'

STOCK_TRANSACTIONS_Details_Nar

STOCK TRANSACTIONS (Details Narrative) (USD $)	3 Months Ended		43 Months Ended
STOCK TRANSACTIONS (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Employee agreement with Eric Clemons [Member]	'	'	'
Recognized expense	$41,084	$0	'
Total expense	'	'	205,419
Common stock vested options	200,000	'	200,000
Employee Agreement With Wesley Tate [Member]	'	'	'
Recognized expense	20,541	0	'
Total expense	'	'	102,706
Common stock vested options	100,000	'	100,000
On August 27, 2013 [Member]	'	'	'
Recognized expense	62,000	0	'
On July 23, 2013 [Member]	'	'	'
Recognized expense	$256,000	$0	'

OPTIONS_AND_WARRANTS_Details

OPTIONS AND WARRANTS (Details) (USD $)	3 Months Ended
OPTIONS AND WARRANTS (Details) (USD $)	Sep. 30, 2013
Warrants	'
Outstanding, beginning of year	62,500
Granted	100,000
Exercised	'
Expired/Forfeited	-12,500
Outstanding, September 30, 2013	150,000
Exercisable at September 30, 2013	150,000
Incurred expense	$157,200
Weighted Average Exercise Price	'
Outstanding, beginning of year	0.32
Granted	$0.20
Exercised	'
Expired/Forfeited	$0.80
Outstanding, September 30, 2013	0.2
Exercisable at September 30, 2013	$0.20
Options	'
Outstanding, beginning of year	1,500,000
Granted	'
Exercised	'
Expired/Forfeited	'
Outstanding, September 30, 2013	1,500,000
Exercisable at September 30, 2013	300,000
Expected to be vested	1,200,000
Incurred expense	$308,125
Options Average Exercise Price	'
Outstanding, beginning of year	$0.50
Granted	'
Exercised	'
Expired/Forfeited	'
Outstanding, September 30, 2013	$0.50
Exercisable at September 30, 2013	$0.50
Expected to be vested	$0.50

OPTIONS_AND_WARRANTS_Details_N

OPTIONS AND WARRANTS (Details Narrative) (USD $)	3 Months Ended		43 Months Ended
OPTIONS AND WARRANTS (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Employee agreement with Eric Clemons [Member]	'	'	'
Recognized expense	$41,084	$0	'
Total expense	'	'	205,419
Common stock vested options	200,000	'	200,000
Employee Agreement With Wesley Tate [Member]	'	'	'
Recognized expense	20,541	0	'
Total expense	'	'	$102,706
Common stock vested options	100,000	'	100,000

RELATED_PARTY_TRANSACTIONS_Det

RELATED PARTY TRANSACTIONS (Details Narrative) (USD $)	Sep. 30, 2013
Related Party Transactions Details Narrative	'
Outstanding balance of related party paybles	$332,700
Accrued interest	$57,685

EARNINGS_PER_SHARE_Details

EARNINGS PER SHARE (Details) (USD $)	3 Months Ended		43 Months Ended
EARNINGS PER SHARE (Details) (USD $)	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Earnings Per Share Details	'	'	'
Net loss attributable to the common stockholders	($725,647)	($285,759)	($3,511,676)
Basic weighted average outstanding shares of common stock	32,927,827	31,180,001	'
Dilutive effect of options and warrants	'	'	'
Diluted weighted average common stock and common stock equivalents	32,927,827	31,180,001	'
Earnings (loss) per share:	'	'	'
Basic and diluted	($0.02)	($0.01)	'

EARNINGS_PER_SHARE_Details_Nar

EARNINGS PER SHARE (Details Narrative) (USD $)	3 Months Ended
EARNINGS PER SHARE (Details Narrative) (USD $)	Sep. 30, 2013	Sep. 30, 2012
Earnings Per Share Details Narrative	'	'
Total dilutive warrants	1,650,000	87,500
Exercise price	$0.30	'